Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Appointment:
Topics:
Countries:
Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.
Publications
-
Walter EB, Schlaudecker EP, Talaat KR, Rountree W, Broder KR, Duffy J, et al. Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial. Vaccine. 2025 Dec 10;72:128072.Chung JR, Price AM, Zimmerman RK, Moehling Geffel K, House SL, Curley T, et al. Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season. Clin Infect Dis. 2025 Nov 6;81(4):e184–91.Campbell PM, Ess GJ, Lale A, Talaat KR, Barnett ED, Pelton SI, et al. Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews. Vaccine. 2025 Oct 24;65:127781.Harit D, Sawant S, Spreng RL, Gurley S, Schechter A, Sharak A, et al. Qualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials. Vaccine. 2025 Oct 3;64:127699.
See more publications at Scholars@Duke